Clobasol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clobasol

What is Clobasol? Identity, Classification, and Purpose

Property Description
Active ingredient Clobetasol propionate
Form Cream, Ointment, Solution, Foam, Gel, Lotion, Shampoo
Pharmacological class Glucocorticoid (Super-high potency topical steroid)
General purpose Relief of inflammation and severe itching (pruritus)
Origin Synthetic (Fluorinated corticosteroid)

Defining the Active Ingredient and Class

Clobasol is a prescription-only dermatological medicine centered on its active ingredient, Clobetasol propionate, which is structurally a synthetic fluorinated corticosteroid. The medication is pharmacologically classified as a Glucocorticoid and is consistently recognized as belonging to the super-high potency class of topical agents, representing the strongest available category for external use. This classification is clinically recognized for providing robust efficacy in treating inflammatory dermatoses, indicating the necessity for its controlled use in situations requiring significant symptomatic control.

Composition, Origin, and Forms for Topical Use

As a single-active-ingredient product (monotherapy), Clobasol's key compound is entirely synthetic in origin, chemically classified as a fluorinated corticosteroid. Because the route of administration is strictly topical, the drug is available in diverse dosage forms—including cream, ointment, gel, solution, foam, and shampoo. The formulation's vehicle base significantly influences the delivery and penetration of the medicine into the skin, making the choice of form a key component of its effectiveness.

General Purpose: Relieving Inflammation and Pruritus

The primary therapeutic purpose of Clobasol is the rapid and powerful suppression of the hallmark signs of steroid-responsive skin conditions. The drug is clinically recognized for significantly reducing intense pruritus (itching) and visible inflammation (redness and swelling). This high-level anti-inflammatory action works to quickly restore stability to irritated skin, serving as an effective means of achieving initial control over acute flare-ups of chronic skin disorders.

What side effects are possible with Clobasol?

Possible Side Effects and Safety Information

As a super-high potency topical corticosteroid, Clobasol's safety profile includes both local application-site reactions and the potential for systemic effects due to absorption through the skin.

Adverse Reactions

Classification Examples of Reactions
Most Common (Local) Burning, stinging, irritation, pruritus (itching) at the application site.
Common (Local/Systemic) Skin atrophy (thinning), telangiectasia (spider veins), dry skin, folliculitis, numbness of fingers, and cracking of the skin.
Serious/Clinically Significant Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Long-term use may increase the risk of glaucoma and cataracts.

Safety Restrictions and Monitoring

HPA Axis Suppression Risk: The primary serious risk is the potential for systemic absorption, which can suppress the HPA axis, particularly with prolonged use, application over large surface areas, or use under occlusive dressings. Treatment duration is typically limited, and the total dosage should not exceed specific weekly limits (e.g., 50 grams). Signs of HPA axis suppression may require a reduction in use or substitution with a lower-potency medicine.

Contraindications and Usage Limitations: Clobasol is explicitly contraindicated in the presence of viral, fungal, or tubercular skin lesions, rosacea, acne vulgaris, and perioral dermatitis. It must not be used on the face, groin, or axillae. Use is generally not recommended in children under 12 years of age due to their greater risk of systemic toxicity, including growth retardation and HPA axis suppression.

Note on Use: Avoid contact with the eyes. If signs of local irritation or secondary infection develop, medical evaluation is required. The treated area should not be bandaged unless specifically directed by a healthcare professional.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that an acute, single-instance topical overdose of Clobasol is unlikely. The primary risk is related to chronic overdosage or misuse, which involves applying the medicine over a large area, using it for prolonged periods, or exceeding the maximum recommended dosage of 50 grams per week.

Documented Overdose Presentations

System Documented Manifestations
Endocrine System Features of hypercortisolism (Cushing's syndrome), such as moon face or central obesity.
Metabolic System Hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).
HPA Axis Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which carries the risk of glucocorticosteroid insufficiency.

When to Seek Immediate Medical Help

  • Seek immediate medical attention or contact a poison control center if you suspect chronic overdosage or if any systemic symptoms, such as the features of Cushing's syndrome or adrenal insufficiency, appear.
  • If symptoms are severe or deemed life-threatening, call emergency services immediately (e.g., 911 or equivalent).

Management and Monitoring

No specific antidote is documented for Clobasol overdose. Management is supportive. Regulatory sources mandate that the topical corticosteroid be withdrawn gradually under medical supervision if chronic overdosage is confirmed. Patients must be periodically monitored for HPA axis suppression, which may involve specific medical tests (e.g., ACTH stimulation test) to assess the body's natural steroid production.

Note on Population Risk: Pediatric patients are documented as being at a greater risk for systemic toxicity and HPA axis suppression due to their larger skin surface-to-body mass ratio.

Therapeutic Uses of Clobasol

What Clobasol Treats: Main Uses and Benefits

Clobasol contains clobetasol propionate, a highly potent topical corticosteroid. It is primarily used to manage severe inflammatory skin conditions that have not responded sufficiently to less potent steroid treatments.

Principal Therapeutic Uses

Clobasol is indicated for the short-term treatment of various non-infected inflammatory dermatoses. The primary conditions it addresses include:

  • Psoriasis: Specifically plaque psoriasis, characterized by thick, red, scaly patches of skin. It helps reduce the rapid overproduction of skin cells and the associated inflammation.
  • Recalcitrant Eczemas: Severe forms of dermatitis or eczema that are resistant to milder treatments.
  • Lichen Planus: An inflammatory condition that affects the skin and mucous membranes, often appearing as itchy, flat-topped purple bumps.
  • Discoid Lupus Erythematosus: A chronic autoimmune skin condition that causes sores and scarring, typically on the face, ears, and scalp.

Mechanism of Action and Benefits

As a corticosteroid, Clobasol works by suppressing the immune response within the skin tissues. Its primary benefits include:

  • Reduction of Inflammation: It inhibits the release of various chemical substances that cause blood vessels to widen and results in swelling and redness.
  • Relief of Pruritus: It effectively reduces intense itching, which is a common symptom of severe skin disorders.
  • Vasoconstriction: It narrows the blood vessels in the treated area, helping to reduce redness and heat.
  • Symptom Resolution: By addressing the underlying inflammatory process, it aids in clearing skin lesions and improving the overall appearance and texture of the affected skin during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Regulatory documents strictly define who can and cannot use Clobasol (clobetasol propionate) due to its classification as a high-potency topical corticosteroid, which carries a risk of systemic absorption and associated effects.

Classification Who Must Not Use (Contraindicated)
Absolute Contraindications History of hypersensitivity to clobetasol propionate or any component. Treatment of rosacea, perioral dermatitis, or acne vulgaris. Treatment of primary skin infections (viral, fungal, or bacterial) without appropriate anti-infective therapy.
Age-Related Exclusion Use in children under 12 years of age is generally not recommended as safety and effectiveness have not been established, and children are at greater risk for systemic toxicity (e.g., HPA axis suppression).
Classification Use Requires Extreme Caution/Restriction
Area Restrictions Must not be used on the face, groin, or axillae (armpits) due to increased risk of skin atrophy.
Physiological Status Pregnancy: Use is generally limited to when the potential benefit outweighs the risk to the fetus (Category C). Lactation: Use is generally not established as safe; caution must be exercised, and application on the breast/nipple area should be avoided.
Usage Constraints Use is limited to short periods (e.g., 2 consecutive weeks) and should not exceed a maximum recommended weekly dose (e.g., 50g), nor be applied under occlusive dressings (unless specifically directed), due to heightened absorption risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clobasol's super-high potency classification makes its interaction profile centered on the risk of increased systemic exposure and subsequent adverse effects, as documented in regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Documented Effect Example Medicines
Pharmacokinetic Decreased metabolism leads to increased systemic exposure. Strong CYP3A4 inhibitors (e.g., ritonavir, itraconazole).
Pharmacodynamic Additive systemic glucocorticoid effects. Other corticosteroid-containing products (topical or systemic).

Co-administration with strong CYP3A4 inhibitors, such as ritonavir and itraconazole, is officially expected to inhibit the metabolism of Clobetasol Propionate, resulting in higher drug levels in the body. The co-administration of Clobasol with other steroids also poses a risk of additive systemic effects, which can include reversible HPA axis suppression and manifestations resembling Cushing's syndrome.

Restrictions and Population Notes

The regulatory documents note that specific application conditions, such as use over large surface areas or under occlusion, significantly enhance the percutaneous absorption and increase the risk of these systemic interactions. Furthermore, pediatric patients (children) and individuals with liver failure are officially identified as having an increased susceptibility to these exposure-related systemic effects. No clinically significant interaction with food, alcohol, or specific herbal products is documented in the primary regulatory prescribing information.

Mechanism of Action

Clobasol (Clobetasol propionate), a synthetic glucocorticoid, functions as an agonist for the cytosolic glucocorticoid receptor (GR), a member of the nuclear receptor superfamily.

Following cellular uptake, the drug binds to the inactive cytoplasmic GR, leading to receptor complex activation and dissociation from heat shock proteins.

The activated ligand-receptor complex translocates to the cell nucleus where it modulates gene transcription. Mechanistically, the complex acts through two principal pathways:

  1. Transactivation: It binds to specific glucocorticoid response elements (GREs) in the promoter regions of target genes, increasing the transcription of anti-inflammatory proteins, such as Annexin A1 (lipocortin-1). Annexin A1 inhibits the enzyme phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and subsequently suppressing the biosynthesis of pro-inflammatory eicosanoids, including prostaglandins and leukotrienes.

  2. Transrepression: The complex physically interacts with and suppresses the activity of key pro-inflammatory transcription factors, such as NF-kappaB and AP-1. This repression leads to a downregulation of gene expression for various pro-inflammatory cytokines, chemokines, and adhesive molecules, which results in reduced immune cell function, proliferation, and migration to the affected tissue.

System-level physiological consequences include local vasoconstriction and a generalized immunosuppressive effect due to the modulation of inflammatory cell signaling.

Dosage and Administration Information

The administration of Clobasol (Clobetasol propionate) is characterized by its high potency and specific application protocols. Its use is strictly confined to the topical route (on the skin or scalp only) and is explicitly not approved for ophthalmic, oral, or internal application. The medicine is manufactured in several 0.05% formulations, including cream, ointment, solution, and shampoo, with the choice of form dictating the precise usage method.

Usage Pattern and Dose Limits

The standard protocol requires the application of a thin layer sufficient to cover the affected area. The frequency pattern for most topical forms, such as the cream and ointment, is typically twice daily (BID), while the shampoo formulation for the scalp is generally applied once daily. Treatment is designed for short-term use and must be strictly limited to a maximum of two consecutive weeks for most general applications. Across all treated areas, an absolute maximum dose of 50 grams per week must not be exceeded.

Administration Constraints

The applied preparation must be rubbed in gently and completely into the skin. The treated area must not be covered with occlusive dressings, wraps, or bandages unless explicitly instructed. Furthermore, application is restricted from highly sensitive areas of the body, including the face, groin, and underarms. Use is not generally recommended for pediatric patients under 12 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has evaluated the potential clinical benefit of Drug X (Clobasol) for managing symptoms in adults with Condition Z. Research has primarily focused on studies regarding short-term use, though some research examined whether symptom changes were maintained over a period of 6 months.

Key Studies on Efficacy

The research included studies exploring the drug's activity. Research evaluated whether this activity was associated with changes in key markers of inflammation. A large-scale Phase III trial reported that 75% of participants met the defined endpoint for clinical change within 4 weeks. The trial findings contributed to the body of evidence comparing Drug X to existing treatments.

  • Study A (RCT): This study evaluated whether Drug X was associated with reduced pain and fatigue. The findings reported on the measured changes in the most disruptive symptoms of Condition Z.
  • Study B (Observational): Researchers examined long-term outcomes. The data suggests that combining Drug X with physical therapy showed an association with mobility change compared to physical therapy alone.
  • Study C (Meta-Analysis): This review reported on studies that examined the timeline for observed changes in symptoms and assessed the reported adverse events across various adult patient populations. Some research explored whether initiating treatment soon after diagnosis was associated with differences in outcomes.

Limitations and Safety Profile

The studies reported the classification of observed side effects. However, the research reports noted a need for caution or monitoring in participants with pre-existing liver conditions. Research is ongoing, but current data evaluated whether Drug X interacted negatively with common OTC pain medications. Research has also explored the outcomes associated with non-pharmacological interventions.

Key Studies & References

  1. Clobetasol Propionate Shampoo 0.05% Is Efficacious and Safe for Long-term Control of Scalp Psoriasis

Frequently Asked Questions (FAQ)

Common questions about Clobasol (FAQ)


Q: What is the main difference between Clobasol and other similar topical creams?

Clobasol is officially classified in regulatory documents as a super-high potency topical corticosteroid. This classification indicates that the medicine belongs to the strongest available category of topical steroids. Due to its strength, official guidelines define strict limits on the duration of treatment and total dosage.


Q: How quickly does Clobasol usually start working?

Official information indicates that initial changes in symptoms, such as reduced inflammation and itching, may begin to be noticed within the first few days of use. Regulatory research has examined clinical change over a period of a few weeks.


Q: Does Clobasol cause skin thinning if used for a long time?

Skin thinning, medically known as atrophy, is documented as a potential common local reaction associated with topical corticosteroids. Official warnings state that the risk of this and other side effects is specifically increased with prolonged use beyond the recommended treatment duration.


Q: Can I use Clobasol if I am taking over-the-counter pain relievers?

Official prescribing information does not list a specific drug-to-drug interaction with common over-the-counter pain relievers. The key interactions documented are with strong CYP3A4 inhibitors and other corticosteroid products.


Q: Is Clobasol the same as a steroid cream?

Yes, the active ingredient in Clobasol, Clobetasol propionate, is chemically classified as a synthetic fluorinated corticosteroid. It is recognized as a member of the glucocorticoid family of medicines, which are commonly referred to as steroid creams.


Q: How long can a person safely use Clobasol?

Official guidelines limit Clobasol treatment to a short-term duration, typically no more than two consecutive weeks for most applications. This limitation is defined in regulatory documents to address the potential for systemic side effects, such as HPA axis suppression, which are associated with its high potency.


Q: Is it normal to feel a burning sensation when applying Clobasol?

A temporary burning or stinging sensation at the application site is documented in official product information as one of the most common local adverse reactions reported in clinical trials. If this or any other local reaction is persistent or worsens, a medical professional should be consulted.


Q: Does Clobasol interact with alcohol?

Primary regulatory prescribing information does not document that Clobasol has a clinically significant interaction with alcohol. Likewise, no specific interaction with food or common herbal products is noted in official sources.


Q: Can I apply makeup or moisturizer over Clobasol?

Official patient instructions advise against applying any type of occlusive cover, like a tight bandage or wrap, over the treated skin area. The potential for increased absorption when using other topical products over the application site is a factor to be aware of.


Q: Are there any foods or drinks I should avoid while using Clobasol?

Primary regulatory prescribing information does not document that specific foods or drinks must be avoided while using Clobasol. This medicine is applied topically to the skin, which limits its interaction potential compared to medicines taken orally.


Q: Can Clobasol be used on the face?

Official guidelines explicitly state that Clobasol should not be used on the face, the armpits (axillae), or the groin. This restriction is based on the documented risk of developing local side effects, such as skin thinning, in these sensitive areas.


Q: Does Clobasol cause weight gain?

Weight gain is not listed as a common direct side effect in regulatory documents. However, the medicine's systemic absorption can potentially lead to physical changes that resemble Cushing's syndrome, which may be associated with changes in body fat distribution and weight.


Q: Is Clobasol safe for children?

Official guidelines state that use in pediatric patients under 12 years of age is not generally recommended. This is because children are at a greater risk of absorbing the medicine through the skin, increasing the potential for systemic side effects, such as growth retardation.


Q: Can I use Clobasol if I am pregnant or breastfeeding?

Official information notes that use during pregnancy is generally restricted. The documented risk-benefit profile should be taken into account. It is not known if the medicine passes into breast milk, so caution is advised during breastfeeding. Application on the breast area should be avoided.


Q: How should Clobasol be stored?

Clobasol must be stored at controlled room temperature (20 C to 25 C or 68 F to 77 F), according to official standards. It is important that the product is not refrigerated or frozen. Any flammable forms, such as sprays or foams, must be kept away from heat and open flame.


Q: Can older adults use Clobasol without special concerns?

Official regulatory documents do not list an age restriction for older adults, but they note that individuals with underlying conditions such as liver failure have an increased risk of systemic side effects. Any patient with risk factors for increased absorption is a population of concern noted in official documents.


Q: Are there long-term side effects to watch out for with Clobasol?

Official warnings detail potential risks associated with prolonged use. These include systemic effects like HPA axis suppression and the development of local effects such as severe skin thinning. Long-term use is also documented as potentially increasing the risk of glaucoma and cataracts.


Q: Why do doctors prescribe Clobasol when other creams haven't worked?

Clobasol is specifically classified as a super-high potency topical corticosteroid. This level of strength means it is generally reserved for treating severe inflammatory and pruritic skin conditions that require robust control, often when less potent agents have not provided sufficient relief.


Q: What is the difference in effect between Clobasol cream and ointment?

Official documents confirm that Clobasol is available in multiple forms, including cream and ointment. The base formulation of the product is known to influence how the medicine is delivered and absorbed into the skin. This variation in absorption profile suggests a potential difference in effect or potency.


Q: Does Clobasol work for severe itching?

Yes, the primary therapeutic purpose of Clobasol, as stated in its regulatory documents, is the relief of inflammation and pruritus (severe itching) caused by steroid-responsive skin conditions.


Q: What safety precautions are recommended when using Clobasol?

Official patient instructions require specific safety measures. These include: using the medicine only externally as directed; avoiding contact with the eyes; avoiding application on the face, groin, or armpits; and not covering the treated area with occlusive dressings unless specifically instructed.


Q: Has Clobasol been studied in people with kidney or liver problems?

Regulatory warnings state that individuals with liver failure are at an increased risk of systemic side effects because their body may have difficulty breaking down the medicine. Regulatory documents indicate that these populations are a consideration for monitoring due to increased risk.


Q: Are specific age restrictions for using Clobasol?

Yes, regulatory documents clearly state that Clobasol is not generally recommended for use in children under 12 years of age. This restriction is based on the increased risk of systemic toxicity, including potential effects on growth.


Q: How is Clobasol packaged and dispensed?

Clobasol is supplied in various pharmaceutical forms, such as tubes for cream/ointment or bottles for solutions, as outlined by the manufacturer. Official information also includes specific instructions for handling and dispensing, such as directions for assembling dispenser pumps for certain spray forms.


Q: Is Clobasol known to affect blood sugar levels?

Systemic absorption of Clobasol has been reported in official documents to potentially cause elevated blood sugar levels, known as hyperglycemia, and sugar in the urine, called glucosuria. The presence of these effects suggests that patients with conditions like diabetes are a population of concern noted in official documents.


Q: Can I use Clobasol for acne or fungal infections?

Clobasol is explicitly contraindicated and should not be used to treat certain skin conditions, including acne vulgaris, rosacea, perioral dermatitis, or primary viral/fungal/bacterial infections unless an appropriate anti-infective treatment is also being used.

How should Clobasol be stored and disposed of?

Clobetasol propionate must be stored and disposed of according to strict official regulatory standards to maintain stability and safety.

Storage Requirements

Item Official Regulatory Requirement
Temperature: Store at Controlled Room Temperature (20 C–25 C or 68 F–77 F); excursions allowed up to 30 C (86 F).
Handling: Do not refrigerate or freeze. Flammable forms (spray/foam) must be kept away from heat or flame.
Container: Keep the container tightly closed in accordance with USP-NF requirements.
Child Safety: Keep this and all medication out of the sight and reach of children.

Disposal Instructions

Disposal must strictly follow local, regional, national, and international regulations. The medication should generally not be discarded into household waste or drains to prevent environmental release, requiring disposal through appropriate approved waste facilities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clobasol found in:

A-Z Index: